| Literature DB >> 35412389 |
Jodi Garvin1, Marharyta Semenikhina2,3, Qiuli Liu1, Kevin Rarick1, Elena Isaeva2, Vladislav Levchenko2,4, Alexander Staruschenko2,4, Oleg Palygin2,3,5, David Harder2, Susan Cohen1.
Abstract
Hyperglycemic conditions are prodromal to blood-brain barrier (BBB) impairment. The BBB comprises cerebral microvessel endothelial cells (CMECs) that are surrounded by astrocytic foot processes. Astrocytes express high levels of gap junction connexin 43 (Cx43), which play an important role in autocrine and paracrine signaling interactions that mediate gliovascular cross talk through secreted products. One of the key factors of the astrocytic "secretome" is vascular endothelial growth factor (VEGF), a potent angiogenic factor that can disrupt BBB integrity. We hypothesize that high-glucose conditions change the astrocytic expression of Cx43 and increase VEGF secretion leading to impairment of CMEC barrier properties in vitro and in vivo. Using coculture of neonatal rat astrocytes and CMEC, we mimic hyperglycemic conditions using high-glucose (HG) feeding media and show a significant decrease in Cx43 expression and the corresponding increase in secreted VEGF. This result was confirmed by the analyses of Cx43 and VEGF protein levels in the brain cortex samples from the type 2 diabetic rat (T2DN). To further characterize inducible changes in BBB, we measured transendothelial cell electrical resistance (TEER) and tight junction protein levels in cocultured conditioned astrocytes with isolated rat CMEC. The coculture monolayer's integrity and permeability were significantly compromised by HG media exposure, which was indicated by decreased TEER without a change in tight junction protein levels in CMEC. Our study provides insight into gliovascular adaptations to increased glucose levels resulting in impaired cellular cross talk between astrocytes and CMEC, which could be one explanation for cerebral BBB disruption in diabetic conditions.Entities:
Keywords: astrocyte; cerebral microvessel endothelial cell; connexin 43; high-glucose conditions; vascular endothelial growth factor
Mesh:
Substances:
Year: 2022 PMID: 35412389 PMCID: PMC9109795 DOI: 10.1152/ajpregu.00315.2020
Source DB: PubMed Journal: Am J Physiol Regul Integr Comp Physiol ISSN: 0363-6119 Impact factor: 3.210